Navigation Links
Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
Date:11/7/2007

SWIFTWATER, Pa., and LYON, France, Nov. 7 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has initiated Phase II testing of its cell culture-based seasonal influenza vaccine in the U.S.

The initiation of Phase I was announced on Sept 25, 2006. This project is part of a contract awarded in 2005 by the U.S. Department of Health and Human Services (HHS) aimed at accelerating the development of a new cell culture- based influenza vaccine. Phase II trials involving healthy adult volunteers in the U.S. will focus further on the safety profile and immunogenicity of the cell-based vaccine.

This vaccine was developed using the PER.C6(R) cell line, licensed from Dutch biotechnology company, Crucell N.V. PER.C6 Cell technology offers Sanofi Pasteur a promising and reliable production method for seasonal and pandemic influenza vaccines in addition to traditional, proven egg-based production. The production scale potential of the PER.C6 cell line has been demonstrated in a successful bioreactor run of 20,000 liters, suggesting robustness of PER.C6 technology and further showing that this may be a suitable cell line for large-scale manufacturing of its influenza vaccine. This scale-up process was achieved under a subcontracting agreement between Sanofi Pasteur and Lonza Biologics plc (Lonza Group).

As the world leader in the research, development and manufacture of influenza vaccines, Sanofi Pasteur is actively involved in other projects in the U.S. and Europe with the goal of developing new influenza vaccines.

Seasonal Influenza Overview

Influenza is a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes. According to the World Health Organization (WHO), 5-15% of the population is affected with upper respiratory tract infections in annual influenza epidemics. Hospitalization and deaths mainly occur in high-ris
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. Prolexys Pharmaceuticals Initiates Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/23/2014)... Parents and physicians concerned about an increase in adolescents, ... breathe a sigh of relief. According to a new ... worth of data from states with and without medical ... increased use among adolescents. The study is published online ... Adolescent Health . , "Any time a state ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
(Date:4/22/2014)... are small cell lung cancers (SCLC), which grow ... researchers at Virginia Commonwealth University Massey Cancer Center ... to this resistance that may lead to improved ... B-cell lymphoma 2 (Bcl-2) family proteins, which are ... function, this family of proteins can trigger a ...
(Date:4/22/2014)... scientists have found a way to block abnormal cholesterol ... atherosclerosis, the main cause of heart attacks and strokes ... condition develops when fat builds inside blood vessels over ... reducing their ability to feed oxygen-rich blood to the ... of experiments, described April 7 in the journal ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... ST. LOUIS, Aug. 18 Reliv International, Inc. (Nasdaq: ... and business tools for its independent distributors here at its 21st annual ... Highlights of the conference included: , , The ... exclusive "r( )collection" of personal care products. (See www.re ...
... Hospitals, Physicians Work Together to Cut Costs, Improve ... 18 Twelve New Jersey hospitals and their participating physicians are ... that will evaluate gainsharing as an innovative new incentive method that ... , "Rising healthcare costs are a growing burden ...
... , SUNNYVALE, Calif., Aug. 18 ... systems including the Expresso Fitness Virtual Reality Bike, announced today ... excess of $6 million from Sierra Ventures, Physic Ventures, and ... company to enhance and accelerate new features and functionality to ...
... , OKLAHOMA CITY, Aug. 18 Almost everyone ... ar a cts at some point. As more Americans ... cataract basics: risks and symptoms, tips that may delay onset, and how to ... , , August is Cataract Awareness Month, and the Oklahoma ...
... AUSTIN, Texas, Aug. 18 Almost everyone who lives a ... some point. As more Americans live into their 70s and beyond, we ... that may delay onset, and how to decide when it is time ... August is Cataract Awareness Month, and the Texas Ophthalmological Association (TOA) ...
... of polyphenols , TUESDAY, Aug. 18 (HealthDay News) -- ... is a great source of natural antioxidants, new research ... the University of Scranton, in Pennsylvania, and his team ... many common, grain-based snacks contain substantial amounts of polyphenols, ...
Cached Medicine News:Health News:Reliv International Launches New Products and Business Tools at 21st International Conference 2Health News:Reliv International Launches New Products and Business Tools at 21st International Conference 3Health News:Update: Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Expresso Fitness(R) Announces $6M Series D Funding 2Health News:Expresso Fitness(R) Announces $6M Series D Funding 3Health News:What Oklahomans Should Know About Cataract Surgery 2Health News:What Oklahomans Should Know About Cataract Surgery 3Health News:What Texans Should Know about Cataract Surgery 2Health News:What Texans Should Know about Cataract Surgery 3Health News:Antioxidants Abound in Cereals, Popcorn, Whole-Grain Snacks 2Health News:Antioxidants Abound in Cereals, Popcorn, Whole-Grain Snacks 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: